Rosalind Advisors, Inc.

Rosalind Advisors, Inc. reported 46 holdings worth US$312M as of Sep 30, 2026 (Form 13F)

As of Sep 30, 2026 · Filed Nov 16, 2026

Rosalind Advisors, Inc. reported 46 holdings worth US$312M as of Sep 30, 2026. Largest: Delcath Systems, Inc., Verastem, Inc. and Fennec Pharmaceuticals Inc. Filed Nov 16, 2026 (Form 13F).

Holdings
46
Value as reported
US$312M

The filing in full

CompanySharesValue as reported% of portfolio
Delcath Systems, Inc.3.3MUS$52.7M16.9%
Verastem, Inc.4.24MUS$34.1M10.9%
Fennec Pharmaceuticals Inc.3.19MUS$34M10.9%
Xeris Biopharma Holdings, Inc.2.58MUS$24.7M7.9%
Cybin, Inc.1.39MUS$17.1M5.5%
Savara, Inc.3.18MUS$16.4M5.3%
Replimune Group, Inc.1MUS$13.2M4.2%
Vor Biopharma Inc.609KUS$11.6M3.7%
X4 Pharmaceuticals, Inc.3.21MUS$9.32M3.0%
Aquestive Therapeutics, Inc.2MUS$9.26M3.0%
Vaxcyte, Inc.149KUS$8.5M2.7%
Protara Therapeutics, Inc.2.4MUS$7.32M2.3%
Myomo Inc.3.92MUS$6.11M2.0%
BioCryst Pharmaceuticals, Inc.722KUS$6.01M1.9%
Rocket Pharmaceuticals, Inc.2.2MUS$5.79M1.9%
PepGen Inc.2MUS$4.84M1.6%
Profound Medical Corp828KUS$4.8M1.5%
Talphera, Inc.4.13MUS$4.8M1.5%
NeurAxis, Inc.548KUS$4.04M1.3%
Ovid Therapeutics Inc.1.11MUS$2.76M0.88%
InspireMD Inc.3.91MUS$2.62M0.84%
Acumen Pharmaceuticals, Inc.1.1MUS$2.44M0.78%
EyePoint, Inc.696KUS$2.28M0.73%
Abivax SA20,869US$2.07M0.66%
Biofrontera Inc.1.79MUS$1.93M0.62%
Atea Pharmaceuticals, Inc.280KUS$1.46M0.47%
CG Oncology, Inc.20,000US$1.42M0.45%
Spruce Biosciences, Inc.26,517US$1.29M0.41%
Kura Oncology, Inc.100KUS$1.07M0.34%
Grace Therapeutics, Inc.476KUS$1.02M0.33%
OnKure Therapeutics, Inc.67,506US$184K0.06%
Celldex Therapeutics, Inc.0US$00.00%

Source

Download original · View original at SEC

Related